Patrick J Lao

List of Publications by Year
in descending order

43 papers	966 citations	471061 17 h-index	476904 29 g-index
48 all docs	48 docs citations	48 times ranked	1385 citing authors

#	Article	IF	Citations
1	Automatic quantification of white matter hyperintensities on T2-weighted fluid attenuated inversion recovery magnetic resonance imaging. Magnetic Resonance Imaging, 2022, 85, 71-79.	1.0	6
2	White matter microstructure associations to amyloid burden in adults with Down syndrome. NeuroImage: Clinical, 2022, 33, 102908.	1.4	1
3	Probing the proteome to explore potential correlates of increased Alzheimer'sâ€related cerebrovascular disease in adults with Down syndrome. Alzheimer's and Dementia, 2022, 18, 1744-1753.	0.4	4
4	Amyloid, cerebrovascular disease, and neurodegeneration biomarkers are associated with cognitive trajectories in a racially and ethnically diverse, community-based sample. Neurobiology of Aging, 2022, 117, 83-96.	1.5	3
5	Obstructive sleep apnea, cerebrovascular disease, and amyloid in older adults with Down syndrome across the Alzheimerâ€™s continuum. SLEEP Advances, 2022, 3, .	0.1	1
6	Jointâ€label fusion brain atlases for dementia research in Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	1
7	Plasma pâ€tau181, pâ€tau217, and other bloodâ€based Alzheimer's disease biomarkers in a multiâ€ethnic, community study. Alzheimer's and Dementia, 2021, 17, 1353-1364.	0.4	160
8	Patterns of tau pathology identified with 18 Fâ€MKâ€6240 PET imaging. Alzheimer's and Dementia, 2021, , .	0.4	12
9	Author Response: White Matter Hyperintensities Mediate the Association of Nocturnal Blood Pressure With Cognition. Neurology, 2021, 97, 46-46.	1.5	0
10	Cortical thickness in the right inferior frontal gyrus mediates age-related performance differences on an item-method directed forgetting task. Neurobiology of Aging, 2021, 106, 95-102.	1.5	6
11	Association of Regional White Matter Hyperintensities With Longitudinal Alzheimer-Like Pattern of Neurodegeneration in Older Adults. JAMA Network Open, 2021, 4, e2125166.	2.8	30
12	Tract-defined regional white matter hyperintensities and memory. NeuroImage: Clinical, 2020, 25, 102143.	1.4	24
13	Alzheimerâ€Related Cerebrovascular Disease in Down Syndrome. Annals of Neurology, 2020, 88, 1165-1177.	2.8	34
14	Cerebrovascular disease promotes tau pathology in Alzheimerâ€™s disease. Brain Communications, 2020, 2, fcaa132.	1.5	46
15	APOE Îµ 4 and restingâ€state functional connectivity in racially/ethnically diverse older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12094.	1.2	14
16	Regional white matter hyperintensities predict Alzheimerâ€™sâ€like neurodegeneration. Alzheimer's and Dementia, 2020, 16, e044776.	0.4	1
17	White matter hyperintensities mediate the association of nocturnal blood pressure with cognition. Neurology, 2020, 94, e1803-e1810.	1.5	25
18	Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimer's and Dementia, 2020, 16, 1065-1077.	0.4	52

#	Article	IF	Citations
19	Does Race or Ethnicity Modify the Impact of Age on Cognition in Middle- and Older-Aged Adults?. Innovation in Aging, 2020, 4, 781-781.	0.0	0
20	Letter and Category Fluency Performance Correlates with Distinct Patterns of Cortical Thickness in Older Adults. Cerebral Cortex, 2019, 29, 2694-2700.	1.6	58
21	Imaging neurodegeneration in Down syndrome: brain templates for amyloid burden and tissue segmentation. Brain Imaging and Behavior, 2019, 13, 345-353.	1.1	21
22	Leisure Activity, Brain Î²â€amyloid, and Episodic Memory in Adults with Down Syndrome. Developmental Neurobiology, 2019, 79, 738-749.	1.5	14
23	White Matter Regions With Low Microstructure in Young Adults Spatially Coincide With White Matter Hyperintensities in Older Adults. Frontiers in Aging Neuroscience, 2019, 11, 345.	1.7	1
24	Comparison of longitudinal AÎ² in nondemented elderly and Down syndrome. Neurobiology of Aging, 2019, 73, 171-176.	1.5	13
25	Human brain imaging of nicotinic acetylcholine Î±4Î²2* receptors using [¹⁸<scp>F</scp>]<scp>N</scp>ifene: Selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways. Journal of Comparative Neurology, 2018, 526, 80-95.	0.9	26
26	The use of Centiloids for applying [¹¹C]PiB classification cutoffs across regionâ€ofâ€interest delineation methods. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 332-339.	1.2	22
27	In vivo imaging of inflammation and oxidative stress in a nonhuman primate model of cardiac sympathetic neurodegeneration. Npj Parkinson's Disease, 2018, 4, 22.	2.5	11
28	[¹⁸F]Nifene test-retest reproducibility in first-in-human imaging of Î±4Î²2* nicotinic acetylcholine receptors. Synapse, 2017, 71, e21981.	0.6	13
29	Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 1-9.	1.2	49
30	Human biodistribution and dosimetry of [18 F]nifene, an Î±4Î²2* nicotinic acetylcholine receptor PET tracer. Nuclear Medicine and Biology, 2017, 55, 7-11.	0.3	11
31	Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau. Applied Radiation and Isotopes, 2017, 130, 230-237.	0.7	9
32	Cognitive decline and brain amyloid-Î² accumulation across 3 years in adults with Down syndrome. Neurobiology of Aging, 2017, 58, 68-76.	1.5	59
33	[P1â€“403]: [Fâ€18]AVâ€1451 PET IN NONâ€DEMENTED ADULTS WITH DOWN SYNDROME IS RELATED TO BOTH AMYLOID AND COGNITION. Alzheimer's and Dementia, 2017, 13, P428.	0.4	1
34	In Vivo Comparison of Tau Radioligands ¹⁸F-THK-5351 and ¹⁸F-THK-5317. Journal of Nuclear Medicine, 2017, 58, 996-1002.	2.8	54
35	Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-Î² Burden in Down Syndrome. Journal of Alzheimer's Disease, 2017, 61, 631-644.	1.2	23
36	[O2â€“02â€“06]: ALZHEIMERâ€LIKE PATHOPHYSIOLOGICAL CHANGES IN THE NONâ€DEMENTED DOWN SYNDROME POPULATION. Alzheimer's and Dementia, 2017, 13, P554.	0.4	0

#	Article	IF	Citations
37	P1-274: Patterns of In-Vivo Preclinical TAU and Amyloid Burden Using [F-18]THK5351 and [C-11]PIB. , 2016, 12, P521-P522.		0
38	ICâ€Pâ€195: Patterns of inâ€Vivo Preclinical TAU and Amyloid Burden Using [Fâ€18]THK5351 and [Câ€11]PIB. Alzheimer's and Dementia, 2016, 12, P141.	0.4	0
39	The effects of normal aging on amyloidâ€Î² deposition in nondemented adults with Down syndrome as imaged by carbon 11â€“labeled Pittsburgh compound B. Alzheimer's and Dementia, 2016, 12, 380-390.	0.4	65
40	First-in-Human Evaluation of ¹⁸F-Mefway, a PET Radioligand Specific to Serotonin-1A Receptors. Journal of Nuclear Medicine, 2014, 55, 1973-1979.	2.8	19
41	Changes in the Î±4Î²2* nicotinic acetylcholine system during chronic controlled alcohol exposure in nonhuman primates. Drug and Alcohol Dependence, 2014, 138, 216-219.	1.6	16
42	Deficient Import of Acetyl-CoA into the ER Lumen Causes Neurodegeneration and Propensity to Infections, Inflammation, and Cancer. Journal of Neuroscience, 2014, 34, 6772-6789.	1.7	46
43	PET imaging of acetylcholinesterase inhibitor-induced effects on Î±4Î²2 nicotinic acetylcholine receptor binding. Synapse, 2013, 67, 882-886.	0.6	11